IP Library Patent Application 18487919
Patent Application
App. No. 18/487,919

Process for Preparing Imetelstat

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/487,919
Abstract

The present invention relates to a process for preparing the telomerase inhibitor imetelstat using a 3 steps per cycle solid-phase support bound process comprising the steps of deprotection of the 3′-amino group of the support-bound oligonucleotide, coupling with a 5′-phosphoramidite, and sulfurization with an acyl disulfide, characterized by the absence of an additional capping step in each cycle that is used to prevent unreacted 3′-amino oligonucleotide groups from reacting during subsequent cycles. Imetelstat has formula below.

Claims (11)

1 . A method of synthesizing the N3′→P5′ thiophosphoramidate oligonucleotide imetelstat of formula

the method comprises of

a) providing a first 3′-amino protected nucleotide attached to a solid-phase support of formula (A) wherein PG is an acid-labile protecting group;

b) deprotecting the protected 3′-amino group to form a free 3′-amino group;

c) reacting the free 3′-amino group with a protected 3′-aminonucleoside-5′-O-cyanoethyl-N,N-diisopropylaminophosphoramidite monomer of formula (B′ n ) wherein n=2 to form an internucleoside N3′→P5′-phosphoramidite linkage;

d) sulfurization of the internucleoside phosphoramidite group using an acyl disulfide to form a N3′→P5′ thiophosphoramidate;

e) repeating 11 times in successive order the deprotection step b), the coupling step c) with a protected 3′-aminonucleoside-5′-O-cyanoethyl-N,N-diisopropylamino-phosphoramidite monomer of formula (B′ n ) wherein the protected nucleoside base B′ in monomer (B′ n ) is successively the protected nucleobase B 3 to B 13 in the respective 11 coupling steps, and the sulfurization step d);

f) removing the acid-labile protecting group PG; and

g) cleaving and deprotecting imetelstat from the solid-phase support;

characterized in that no additional capping step is performed in any of the reaction steps a) to e).

2 - 13 . (canceled)

Assignments (3)
PATENT SECURITY AGREEMENT Recorded Nov 12, 2024
From: GERON CORPORATION
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 069341/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2024
From: MUSLEHIDDINOGLU, JALE; GALA, DINESH; ALBANEZE-WALKER, JENNIFER ELIZABETH
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 068959/0205 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2024
From: JANSSEN PHARMACEUTICA NV
To: GERON CORPORATION
Reel/Frame 068959/0237 →